Finance

Lists
Outlook: 81.5% bullish·1.8% bearish
Go to analysis
VRTX:NASDAQ
Vertex Pharmaceuticals Inc
$547.09
+0.85%
(+4.59) 1D
$548.00
+0.17% (+0.91)
After hours
Closed: Nov 6, 4:00:00 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for VRTX...
Open
$531.53
High
$548.76
Low
$531.53
Mkt. cap
138.71B
Avg. vol.
1.44M
Volume
1.27M
P/E ratio
35.20
52-wk high
$568.67
52-wk low
$406.67
EPS
$15.54
Beta
0.28
Shares outstanding
253.54M
No. of employees
6K
Open
$531.53
High
$548.76
Low
$531.53
Mkt. cap
138.71B
Avg. vol.
1.44M
Volume
1.27M
P/E ratio
35.20
52-wk high
$568.67
52-wk low
$406.67
EPS
$15.54
Beta
0.28
Shares outstanding
253.54M
No. of employees
6K
News stories
From web sources and news partners
Profile
Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, Oxfordshire, England. Wikipedia
About Vertex Pharmaceuticals Inc
CEOReshma Kewalramani
Employees6.4K
Founded1989
HeadquartersBoston, Massachusetts, United States
SectorHealth Care
IndustryBiotechnology
Websitevrtx.com
Analyst ratings
Based on 22 analysts giving stock ratings to VRTX in the past 3 months
Strong buy
Buy
20
Hold
2
Sell
0
12-month forecast
Based on 22 Wall Street analysts offering 12 month price targets for VRTX in the last 3 months.
Highest
Current $547.09
$725.00 (+32.52%)
Average
$616.37 (+12.66%)
Lowest
$442.00 (-19.21%)
Analyst
Recommendation
Action
Price target
Projected
Date
Naz Rahman
Maxim Group
Buy
Reiterated
$620.00
+13.3%
11/04/2026
Eliana Merle
Barclays
Buy
Maintained
$626.00
+14.4%
11/04/2026
Ananda Ghosh
H.C. Wainwright
Buy
Reiterated
$641.00
+17.2%
11/04/2026
Evan Seigerman
BMO Capital
Buy
Maintained
$620.00
+13.3%
11/03/2026
Tazeen Ahmad
Bank of America Securities
Buy
Reiterated
$667.00
+21.9%
11/02/2026
Phil Nadeau
TD Cowen
Buy
Maintained
$575.00
+5.1%
11/03/2026
Carter Gould
Cantor Fitzgerald
Buy
Maintained
$619.00
+13.1%
11/02/2026
Louise Chen
Scotiabank
Buy
Reiterated
$660.00
+20.6%
11/03/2026
Brian Abrahams
RBC Capital
Buy
Maintained
$600.00
+9.7%
11/02/2026
Terence Flynn
Morgan Stanley
Buy
Reiterated
$660.00
+20.6%
11/03/2026
Paul Matteis
Stifel Nicolaus
Hold
Maintained
$563.00
+2.9%
11/03/2026
Salveen Richter
Goldman Sachs
Buy
Reiterated
$725.00
+32.5%
11/03/2026
Jessica Fye
J.P. Morgan
Buy
Reiterated
$570.00
+4.2%
11/03/2026
Geoff Meacham
Citi
Buy
Maintained
$585.00
+6.9%
11/03/2026
Mohit Bansal
Wells Fargo
Buy
Reiterated
$650.00
+18.8%
11/02/2026
Michael Yee
UBS
Buy
Maintained
$640.00
+17%
11/04/2026
David Risinger
Leerink Partners
Buy
Reiterated
-
-
10/27/2026
Andrew Fein
H.C. Wainwright
Buy
Maintained
$641.00
+17.2%
10/26/2026
Jeffrey Walch
Bernstein
Buy
Maintained
$608.00
+11.1%
09/25/2026
Akash Tewari
Jefferies
Buy
Maintained
$640.00
+17%
09/23/2026
Unknown Analyst
Jefferies
Buy
Maintained
$640.00
+17%
09/23/2026
Danielle Brill
Truist Financial
Buy
Maintained
-
-
09/23/2026
Whitney Ijem
Canaccord Genuity
Hold
Maintained
$442.00
-19.2%
09/23/2026
Myles Minter
William Blair
Buy
Maintained
-
-
09/22/2026
William Pickering
Bernstein
Buy
Maintained
$608.00
+11.1%
08/11/2026
Andy Chen
Wolfe Research
Buy
Maintained
$557.00
+1.8%
08/03/2026
Cory Kasimov
Evercore ISI
Buy
Maintained
$535.00
-2.2%
08/04/2026
Joseph Stringer
Needham
Hold
Maintained
-
-
08/04/2026
Sadia Rahman
Wells Fargo
Buy
Reiterated
$550.00
+0.5%
07/13/2026
Brian Skorney
Robert W. Baird
Sell
Maintained
$350.00
-36%
07/07/2026
Unknown Analyst
Raymond James
Hold
Maintained
-
-
06/24/2026
Unknown Analyst
Guggenheim
Buy
Maintained
$546.00
-0.2%
06/02/2026
Unknown Analyst
J.P. Morgan
Buy
Maintained
$515.00
-5.9%
05/20/2026
Jay Olson
Oppenheimer
Buy
Maintained
$600.00
+9.7%
05/05/2026
Hans Engel
Erste Group
Hold
Maintained
-
-
05/05/2026
Joon Lee
Truist Financial
Buy
Maintained
$525.00
-4%
03/11/2026
Last report
Nov 2, 2026
Fiscal period
Q3 2026
$4.76 / $4.78
-0.50%miss
Revenue / Est. (USD)
3.44B / 3.43B
+0.17%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
3.19B
2.99B
3.33B
3.44B
Cost of goods sold
1.44B
1.35B
1.48B
1.58B
Cost of revenue
1.44B
1.35B
1.48B
1.58B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
487.00M
493.70M
582.20M
641.10M
Operating expense
487.00M
493.70M
582.20M
641.10M
Total operating expenses
1.93B
1.85B
2.07B
2.22B
Operating income
1.26B
1.14B
1.27B
1.22B
Other non operating income
-14.30M
-6.70M
46.20M
-23.40M
EBT including unusual items
1.33B
1.25B
1.39B
783.40M
EBT excluding unusual items
1.38B
1.25B
1.42B
1.29B
Income tax expense
139.90M
221.50M
292.00M
129.80M
Effective tax rate
10.51%
17.68%
20.98%
16.57%
Other operating expenses
-
-
-
-
Net income
1.19B
1.03B
1.10B
653.60M
Net profit margin
37.34%
34.53%
32.99%
19.00%
Earnings per share
5.03
4.47
4.73
4.76
Interest and investment income
121.90M
114.80M
120.60M
118.40M
Interest expense
-3.30M
-
-
-36.00M
Net interest expenses
118.60M
114.80M
120.60M
82.40M
Depreciation and amortization charges
-
-
-
-
EBITDA
1.29B
1.19B
1.33B
1.29B
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps